

CURRICULUM VITAE

NAME: Alan H. B. Wu, Ph.D., D.A.B.C.C., F.A.C.B.

Position: Chief, Clinical Chemistry and Toxicology Laboratories, San Francisco General Hospital
Professor, Dept. Lab. Medicine, University of California at San Francisco

Address: SF General Hospital
1001 Potrero Ave.
San Francisco, CA 94110

Voice: 415-206-3540
FAX 415-206-3045
email:wualan@labmed2.ucsf.edu

EDUCATION:

1971-1975	Purdue University, W. Lafayette, IN	B.S. Honors, Chemistry, B.S., Biology.
1975-1980	University of Illinois, Urbana, IL	Ph.D. Analytical Chemistry.
1980-1982	Hartford Hospital, Hartford, CT	Post-Doctoral Fellow.

LICENSES, CERTIFICATION:

1984	American Board of Clinical Chemistry Certification: Clinical Chemistry
1985	American Board of Clinical Chemistry Certification: Toxicological Chemistry
2005	State of California, Certified as a Clinical Chemistry Laboratory Director

PRINCIPAL POSITIONS HELD:

1982-1988	Asst. Prof., Dept. Pathology & Lab Medicine, Univ. Texas, Houston
1982-1984	Assoc Director Clinical Chemistry & Toxicology Hermann Hospital, Houston TX
1982-1992	Assoc. Prof., Dept. Pathology & Lab Medicine, Univ. Texas, Houston
1984-1992	Director, Clinical Chemistry Y Toxicology, Hermann Hospital, Houston TX
1982-1994	Faculty, Graduate School of Biomedical Science, Univ. Texas, Houston
1990-1992	Section Chief, Clin Chem Lab, L.B. Johnson General Hospital, Houston
1992-2004	Director, Clin Chem & Toxicology Laboratories, Hartford Hospital, Hartford CT
1993-2004	Associate Professor, Dept. Chemistry, Univ. Connecticut, Storrs
1993-2004	Associate Prof., Dept. Pathobiology, Univ. Connecticut, Storrs
1993-1997	Assoc. Prof., Dept. Laboratory Medicine, Univ. Connecticut, Farmington
1997-2004	Professor, Dept. Laboratory Medicine, Univ. Connecticut, Farmington
1998-2004	Director, Clinical Path, Dept Pathology & Lab Medicine, Hartford Hospital
2004-present	Division Chief, Clinical Chemistry, Dept. Lab Medicine, S.F. General Hospital
2004-present	Professor, Dept. Lab Medicine, Univ. of California at San Francisco

OTHER POSITIONS HELD CONCURRENTLY:

- 1992 Director, Forensic Tox Lab (CAP and NIDA certified), Hermann Hospital
- 1992-2002 Director, Forensic Tox Lab (CAP and NIDA certified), Hartford Hospital
- 1985-1992 Program Director, COMACC-accredited Clinical Chemistry Postdoctoral Program, University of Texas Health Center
- 1992-2004 Program Director, COMACC-accredited Clinical Chemistry Postdoctoral Program, Hartford Hospital
- 2005-present Program Director, COMACC-accredited Clinical Chemistry Postdoctoral Program, University of California, San Francisco
- 2006-present College of American Pathologists, Toxicology Resource Committee

HONORS AND AWARDS:

- 1981 Beckman Conference Fellowship (Travel Grant).
- 1982 Am. Assoc. for Clinical Chemistry (AACC), Endowment Fund for Research.
- 1982 Young Investigator, Academy Clinical Laboratory Physicians & Scientists.
- 1986 AACC National Young Investigator Award.
- 1991 National Academy of Clinical Biochemistry, The George Grannis Award.
- 1991 AACC, Texas Section, Outstanding Clinical Chemist Award.
- 1986, 1992-3, 1995-2002, 2005 AACC Outstanding Speaker Award.
- 1993 Recipient, Michael Ladzinsky Memorial Lectureship, University of Connecticut
- 1999 Best Scientific Paper, Journal of Nuclear Cardiology.
- 2001 National Academy of Clinical Biochemistry, Alvin Dubin Award.
- 2002 ACB/AACC TransAtlantic Lectureship Award.
- 2002 AACC Outstanding Contributions in Education, National Award.
- 2002 AACC New Jersey Section, Bernard F. Gerulat Memorial Award.
- 2002 AACC Capital Section, Reiner Award.
- 2005 IVD Technology's Top Ten Persons in the IVD Industry
- 2005 AACC Connecticut Valley Section, Seligson-Golden Award
- 2006 AACC Northern California Section, Outstanding Contributions to Clinical Chemistry through Education Award
- 2006 Meyer Bodansky Visiting Professor of Experimental Pathology, University of Texas Medical Branch, Galveston
- 2007 AACC Molecular Diagnostics Division, Best Abstract Award.

CLINICAL ACTIVITIES

Director, Clinical Chemistry and Toxicology at San Francisco General Hospital. I supervise all of the professional activities in these laboratories including supervision of all personnel, development and approval of all new laboratory tests and instruments, compliance with regulatory agencies, sign-out reports, and all communications with the house staff and medical staff.

OTHER PROFESSIONAL ACTIVITIES:

MEMBERSHIP in PROFESSIONAL SOCIETIES

Academy Clinical Laboratory Physicians and Scientists

American Academy of Forensic Sciences, Toxicology Division

American Association for Clinical Chemistry

Association of Clinical Biochemists

Connecticut Society of Pathologists, Associate Member

Texas Section American Association for Clinical Chemistry

Connecticut Valley Section American Association for Clinical Chemistry

International Federation of Clinical Chemistry

International Association Therapeutic Drug Monitoring and Clinical Toxicology

National Academy of Clinical Biochemistry

Society of Forensic Toxicology, Member

RECENT INVITED PRESENTATIONS

INTERNATIONAL

The Bergmeyer Conference, Munich, Germany, 1999

International Federation of Clinical Chemistry WorldLab, Florence, Italy, 1999.

Euromedlab 2001, Prague, Czech Republic, 2001.

Australasian Assoc. Clinical Biochemists, Perth, Sydney, Brisbane, Melbourne, Hobart 2001

Chinese Clinical Chemistry and Laboratory Medicine Congress, Hong Kong, China, 2001

Association of Clinical Biochemists, Focus 2002, Glasgow, Scotland, 2002.

18th International Federation of Clinical Chemistry & Laboratory Medicine, Kyoto, Japan, 2002

ProCardio Symposium, Lisbon, Portugal, 2003.

Euromedlab 2003, Barcelona, Spain, 2003.

Charitie Hospital, Grand Rounds, Berlin, Germany, 2003-2006.

Chinese Clinical Chemistry and Laboratory Medicine Congress, Nanjing, China, 2004

The Bergmeyer Conference, Munich, Germany, 2005.

International Heart Forum, Beijing, 2005 and 2006.

NATIONAL

American Association for Clinical Chemistry, Annual Meeting, Chicago, 2001

American Association for Clinical Chemistry, Annual Meeting, Orlando, 2002

American Association for Clinical Chemistry, Annual Meeting, Philadelphia, 2003

American Association for Clinical Chemistry, Annual Meeting, Los Angeles, 2004

Beckman Conference, Boston, MA, 2004.

TEACHING & MENTORING

DIDACTIC TEACHING - Clinical Chemistry Course, PATH235/335, Department of Pathobiology, University of Connecticut, Storrs.

LABORATORY TEACHING – Lecturer, Medical Technology and Medical Licensed Technology Courses, Hartford Hospital

CLINICAL TEACHING – Department of Pathology and Laboratory Medicine Residents.

STUDENTS PERSONALLY SUPERVISED:

Graduate students in the Department of Pathobiology:

Richard Johnson, Ph.D., 1997.

Dustin Yaworsky, Ph.D. 2003.

Mary Zaleski, Ph.D., current.

Kim Marie Della Vecchia, 2002.

Sweda Ghandi, M.S., 2002.

Graduate students in the Department of Chemistry:

Heather Sulkowski, M.S. 1998.

Gina Cassella, M.S. 1998.

Ming Tran, M.S. 2006.

POSTDOCTORAL FELLOWS PERSONALLY SUPERVISED:

Julia Drees, 2005-2007

Ping Wang, 2004-2006

Wieslaw Furmaga, M.D., 2001-2003

Stacey Wieczorek, Ph.D., 1999-2002

Farooq Ghani, M.D., Ph.D., 1997-1999

Yue-Jin Feng, M.D., 1996-1999

John Contois, Ph.D., 1994-1996

TEACHING AWARDS

1983,84,87,88,89 Dean's Teaching Excellence List, University of Texas Medical School
1994,2000 Dept. Pathology, Hartford Hospital, Resident Teaching Award.

SUMMARY OF TEACHING DUTIES:

Last year	300 Total hours of Teaching (including preparation)
2004-2005	Clinical teaching (pathology residents): 250 hours Laboratory teaching (postdoctoral fellows): 50 hours Medical technology instruction: 5 hours
This year	300 Total hours of Teaching (including preparation)
2005-2006	Clinical teaching (pathology residents): 250 hours Laboratory teaching (postdoctoral fellows): 50 hours Medical technology instruction: 5 hours
Anticipated	300 Total hours of Teaching (including preparation)
2006-2007	Clinical teaching (pathology residents): 250 hours Laboratory teaching (postdoctoral fellows): 50 hours Medical technology instruction: 5 hours

EDUCATIONAL COMPUTER SOFTWARE:

1. Wu AHB, Jenkins B, Fath SJ, LaRocco M, Bracey A, Simon FA. Computer assisted learning for clinical pathology. Health Sciences Consortium, Chapel Hill, NC:1989. (13 cases, and 19 sessions).
2. Wu AHB. Clinical chemistry quiz. AACC Press, Washington DC:1990.
3. Wu AHB. Urinalysis tutorial. Warlock Productions, Hanover, NH:1991.
4. Wu AHB. The chemistry profile. Warlock Productions, Hanover, NH:1993.

5. Wu AHB, Wu PL. Methods in clinical chemistry. Warlock Productions, Hanover, NH:1994.
6. Electrophoresis. Warlock Productions, Hanover, NH: 2001.

SERVICE

DEPARTMENTAL SERVICE

- 1992-2004 Dept. Pathology & Laboratory Medicine Residency Steering Committee
 2006-2007 Dept. Laboratory Medicine Search Committee SFGH Laboratory Director
 2007-present Dept. Laboratory Medicine Academic Personnel Manual Committee
 2007 Dept. Pharmacy, Faculty Search Committee

HOSPITAL SERVICE

- 2005-present Advisory Committee to the General Clinical Research Center, SFGH

GOVERNMENT SERVICE

- 1995-2004 Connecticut Poison Control Center Medical Advisory Committee
 2000 State of CT, Drugs Don't Work Committee, Governor's Prevention Partnership.
 2001-2004 State of Connecticut Department of Public Health, Lab Advisory Committee,
 2002-2004 State of CT, Environmental Biomonitoring Committee
 2002-present State of CT, Terrorism Preparedness Committee

SERVICE TO PROFESSIONAL SOCIETIES

- 1985-2003 Commission on Accreditation in Clinical Chemistry, President.
 1990-1996 American Board of Clinical Chemistry, member, Vice President.
 1994-2004 Hartford County Medical Assoc., Committee on Physician Health
 1996-present Am Assoc Clin Chem. Troponin Standardization Committee, Member.
 1997-present Int. Fed. Clin Chem, Standardisation of Markers of Cardiac Damage, Member.
 2005-present Am Assoc Clin Chem. Evidence Based Medicine Committee

SERVICE TO PROFESSIONAL PUBLICATIONS:

- 1993-1999 Editor, "Clinical Chemistry Questions and Answers," *JIFCC*.
 1996-present Editorial Board, *Annals of Clinical and Laboratory Science*.
 1998 Editorial Board, *Clinical Chemistry*.
 1998-present Editor-in-Chief, *Clinica Chimica Acta*.
 1998-present Book Series Editor, *Pathology and Laboratory Medicine*, Humana Press.
 2001-present Editorial Board, *Journal of Point-of-Care Testing and Near-Patient Technology*

PEER REVIEWED PUBLICATIONS:

1. Wu AHB, Malmstadt HV. A versatile microcomputer-controlled titrator. *Anal Chem* 1978;50:1090-6.

2. Wu AHB, Rotunno T, Malmstadt HV. The determination of protein nitrogen in feed and wheat using a microcomputer-controlled titrator. *J Assoc Off Anal Chem* 1978;62:969-75.
3. Wu AHB, Malmstadt HV. Reactions during the titration of ammonia with hypochlorite in the presence of bromide. *Anal Chem* 1981;53:1725-6.
4. Wu AHB, Bowers GN Jr. Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB from BB and macro forms of creatine kinase isoenzymes in patients and healthy individuals. *Clin Chem* 1982;28:2017-21.
5. Wu AHB, Stout R, McComb RB. Falsely high creatinine concentration associated with severe methanol intoxication. *Clin Chem* 1983;29:205-8.
6. Wu AHB, Herson VC, Bowers GN Jr. Macro creatine kinase type 1 and 2: Clinical significance in neonates and children as compared with adults. *Clin Chem* 1983;29:201-4.
7. Wu AHB, Parker OS, Ford L. Hyperviscosity and hyaluronic acid in serum in a case of Wilms' tumor. *Clin Chem* 1984;30:914-6.
8. Wu AHB, Strocchia C, Gornet TG, Edwards J. An inexpensive lyophilized control for cardiac isoenzymes. *Clin Chem* 1994;30:1718.
9. Wu AHB, Gornet TG. Preparation of urine samples for liquid chromatographic determination of catecholamines: bonded - phase phenylboronic acid, cation-exchange resin and alumina adsorbents compared. *Clin Chem* 1985;31:298-302.
10. Wu AHB, Gornet TG, Bretaudiere JP, Panfili PR. Comparison of enzyme immunoassay and immunoinhibition for creatine kinase MB in diagnosis of acute myocardial infarction. *Clin Chem* 1985;31:470-4.
11. Wu AHB, Gornet TG. Measurement of creatine kinase MM sub-type by anion-exchange liquid chromatography. *Clin Chem* 1985;31:1841-5.
12. Spain MA, Wu AHB. Bilirubin interference with determination of uric acid, cholesterol, and triglycerides in peroxidase-coupled systems and the effect of ferrocyanide. *Clin Chem* 1986;32:518-21.
13. Wong SS, Wu AHB. Thrombolytic therapy for acute myocardial infarction. *AACC Ther Drug Monit-Toxicol Update* 1986;8(2):1-4.
14. Wu AHB, Wong SS, Brockie R, Nishikawa, A. Comparison of three cases of acute myocardial infarction treated with thrombolytic therapy. *AACC Ther Drug Monit-Toxicol Update* 1986;8(3):1-4.
15. Bracey A, Wu AHB, Aceves J, Chow T, Carlile S, Hoots WK. Platelet dysfunction associated with Wilms' tumor and hyaluronic acid. *Am J Hematol* 1987;24:247-57.
16. Wu AHB, Bracey A, Bryan-Brown CW, Harper JV, Burritt MF. Ionized calcium monitoring during liver transplantation. *Arch Path Lab Med* 1987;111:935-8.
17. LeMaistre A, Bracey A, Katz A, Wu AHB. The role for qualitative hCG assays in the diagnosis of ectopic pregnancy. *Clin Chem* 1987;33:1908-10.
18. Wong SS, Wu AHB, Fritsche HA. Re-evaluation of creatine kinase BB as a tumor marker. *Clin Chem* 1987;33:809-11.

19. Wu AHB, Gornet TG, Wu VH, Brockie R, Nishikawa A. Early diagnosis of acute myocardial infarction by rapid analysis of creatine kinase isoenzyme-3 (CK-MM) sub-types. *Clin Chem* 1987;33:359-62.
20. Wong SS, Earl R, Wu AHB. Simultaneous presence of IgA- and IgG-CK-BB in a patient without myocardial infarction. *Clin Chim Acta* 1987;166:99-100.
21. Wu AHB, Wong SS, Waldron C, Chan DW. Automated quantitative measurement of human chorionic gonadotropin: analytical correlation between serum and urine with creatinine correction. *Clin Chem* 1987;33:1424-6.
22. Jone CM, Wu AHB. An unusual case of toluene-induced metabolic acidosis. *Clin Chem* 1988;34:2596-9.
23. Wu AHB. Creatine kinase isoforms in ischemic heart disease. *Clin Chem* 1989;35:7-13.
24. Reed RL, Wu AH, Miller-Crotchett P, Crotchett J, Fischer RP. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. *J Trauma* 1989;29:1462-70.
25. Wu AHB, Gornet TG, Harker CC, Chen HL. Role of rapid immunoassays for urgent ("stat") determination of creatine kinase MB. *Clin Chem* 1989;35:1752-6.
26. Peaceman AM, Wu AHB. The use of magnesium sulfate in pregnancy. *AACC Ther Drug Monit-Toxicol Update* 1989;10(8):1-4.
27. Wu AHB, Schwartz JG. Update on creatine kinase isoenzyme assays. *Diag Clin Test* 1989;27(8):16-20.
28. Wu AHB, LaRocco M, Fath SJ, Simon FA. Evaluation of computer case simulations for teaching clinical pathology to second-year medical students. *Ann Clin Lab Sci* 1990;20:152-8.
29. Jone CM, Wu AHB, Spillman T, Fritsche HA. Screening antisera for subtype specificity based on immunoblotting of lectin affinity electrophoresis: application towards alpha fetoprotein subfractions. *J Clin Lab Anal* 1990;4:307-12.
30. Rosano T, Ambrose RT, Wu AHB, Swift TA, Yadegari P. A candidate reference method for serum creatinine: method development and inter-laboratory validation. *Clin Chem* 1990;36:1951-5.
31. Khalil SN, Florence FB, Van den Niewenhuyzen MCO, Wu AHB, Stanley TH. Rectal methohexital: concentration and length of the rectal catheters. *Anest Anag* 1990;70:645-9.
32. Onigbinde TA, Wu AHB, Johnson M, Wu YS, Collinsworth WL, Simmons MJ. Clinical evaluation of an automated chemical inhibition assay for lactate dehydrogenase (LD)-1 isoenzyme. *Clin Chem* 1990;36:1819-22.
33. Gauthier J, Smalling RW, Wu AHB, Buja LM. A clinicopathologic conference: severe anginal pain in a 58-year old man. *Houston Med* 1991;7:58-69.
34. Wu AHB. Pharmacokinetic aspects of ethanol for medico-legal purposes. *AACC Ther Drug Monit-Toxicol Update* 1991;12(12):5-18.

35. Onigbinde TA, Wu AHB. Full-scan gas chromatography-mass spectrometry analysis for drug testing in urine using an ion trap. *AACC Ther Drug Monit-Toxicol Update* 1992;13(7):9-23.
36. Wu AHB. Creatine kinase MM and MB isoforms. *Lab Med* 1992;23(5):303-5.
37. Reed RL, Ericsson CD, Wu A, Miller-Crotchett P, Fischer RP. Pharmacokinetics of prophylactic antibiotics. *J Trauma* 1992;32:21-7.
38. Wu AHB, Johnson KG, Onigbinde TA, Wong SS. Evaluation of full-scanning GC/ion trap MS analysis of drugs of NIDA drugs-of-abuse in urine. *J Anal Toxicol* 1992;16:202-6.
39. Wu AHB, Onigbinde TA, Johnson KG, Wong SS. Identification of methamphetamines and over-the-counter sympathomimetic amines by full-scan GC/Ion trap MS with electron impact and chemical ionizations. *J Anal Toxicol* 1992;16:137-41.
40. Wu AHB, Onigbinde TA, Johnson KG, Wimbish GH. Alcohol-specific cocaine metabolites in serum and urine of hospitalized patients. *J Anal Toxicol* 1992;16:132-6.
41. Wu AHB, Wong SS, Johnson KG, Ballatore A, Seifert WE. The conversion of ephedrine to methamphetamine and methamphetamine-like compounds prior to GC/MS analysis of CB and HBFA derivatives. *Biol Mass Spectrom* 1992;21:278-84.
42. Wu AHB. Therapeutic drug monitoring for the 1990s: meeting the laboratory needs of a changing environment. *Wiener Klin Wochen* 1992;191, Suppl., 19-22.
43. Jarausch J, Collinsworth W, Cano Y, Hafner G, Hammer E, Malandain H, Pokieser L, Redondo FL, Schlebusch H, Taylor A, Thomsen L, Weindel K, Wieland H, Willems D, Windisch M, Woods M, Wu AHB, Zebelmann A. Results of the multicenter evaluation of a novel homogeneous immunoassay for digoxin based on the cloned enzyme donor immunoassay technology. *Wiener Klin Wochen* 1992;191, Suppl., 69-72.
44. Klein G, Collinsworth W, Courbe A, Diez O, Domke I, Hanseler E, Haux P, Kattermann R, Knoke A, Lehmann P, Moia F, Nelson P, Ollerich M, Suigo E, Torralba A, Valdes R Jr, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenobarbital assay. *Wiener Klin Wochen* 1992;191, Suppl., 43-47.
45. Klein G, Collinsworth W, Courbe A, Fuentes-Arderiu X, Graham J, Hanseler E, Hannak D, Kattermann R, Knoke A, Lehmann P, Mastropaolo W, Moia F, Nelson P, Oellerich M, Suigo E, Torralba A, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenytoin assay. *Wiener Klin Wochen* 1992;191, Suppl., 38-42.
46. Klein G, Castineiras MJ, Collinsworth W, Courbe A, Delavenne M, Hanseler E, Hannak D, Kaspar P, Kattermann R, Knoke A, Mastropaolo W, Moia F, Nelson P, Oellerich M, Suigo E, Swanson R, Torralba A, Valdes R Jr, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA theophylline assay. *Wiener Klin Wochen* 1992;191, Suppl., 31-37.
47. Tso G, Wu AHB, Wong SS. Screening for drugs-of-abuse by Syya II reagents. *Res Comm Sub Abuse* 1992;13,256-68.
48. Wu AHB, Johnson KG, Wong SS. Impact of revised HHS guidelines for methamphetamine testing in urine. *Clin Chem* 1992;38:2352-3.

49. Onigbinde TA, Wu AHB, Wu YS, Simmons MJ. Mechanism of differential inhibition of lactate dehydrogenase isoenzymes in the BMD LD-1 assay. *Clin Biochem* 1992;25:425-9.
50. Wu AHB, Wang X-M, Gornet TG, Ordonez-Llanos J. Creatine kinase MB isoforms in patients with myocardial infarction and skeletal muscle injury. *Clin Chem* 1992;38:2396-400.
51. Wu AHB, Perryman MB. Clinical applications of muscle enzymes and proteins. *Curr Opin Rheumatol* 1992;4:815-20.
52. Wu AHB, Gornet TG, Schenkel O, Smith-Cronin L, Graham GA, Tonnesen AS, BA McKinley. Preliminary evaluation of an experimental clinical chemistry analyzer developed for space medicine. *Clin Chem* 1993;39:22-36.
53. Wu AHB, Taylor GR, Graham GA, McKinley BA. The clinical chemistry and immunology of long-duration space missions. *Clin Chem* 1993;39:37-44.
54. Friedman DL, Wu AHB, Gornet TG, Kesterson R, Chen L, Puleo P, Perryman MB. Recombinant creatine kinase proteins and proposed standards for creatine kinase isoenzyme and subform assays. *Clin Chem* 1993;39:1598-601.
55. Wu AHB, Wong SS, Johnson KG, Callies J, Shu DX. Evaluation of the Triage system for emergency testing of phencyclidine, amphetamines, opiates, and tetrahydrocannabinol in serum. *J Anal Toxicol* 1993;17:241-5.
56. Wu AHB, Liu N, Cho YJ, Johnson KG, Wong SS. Extraction and simultaneous elution and derivatization of tetrahydrocannabinol using Toxi-Lab SPEC prior to GC/MS analysis of urine. *J Anal Toxicol* 1993;17:215-7.
57. Caprioli R, Wu AHB. Mass spectrometry. In *Review of Clinical Chemistry*. *Anal Chem* 1993;65:R470-4.
58. Abouleish E, Rawal N, Tobon-Randal B, Rivera-Weiss M, Meyer B, Wu A, Rashad MN. A clinical and laboratory study to compare the addition of 0.2 mg of epinephrine, or their combination to hyperbaric bupivacaine for spinal anesthesia in Casarean section. *Anesth Analg* 1993;77:457-62.
59. O'Connor E, Ostheimer D, Wu AHB. Limitations of forensic urine drug testing by methodology and adulteration. *AACC Ther Drug Monit-Toxicol Update* 1993;14:275-96.
60. Green S, Wu AHB. Immunoassays and electrophoresis for creatine kinase isoenzymes and isoforms in diagnosis and management of acute myocardial infarction. *AACC Endo* 1993;11:329-44.
61. Wong SS, Liu N, Wu AHB. An improved quantitative APT test for the detection of fetal hemoglobin in blood stools of the newborn. *Clin Chem* 1993;39:2326-9.
62. Wu AHB, Ostheimer D, Cremese M, Forte E, Hill D. Characterization of drug interferences caused by coelution of substances in GC/MS confirmation of targeted drugs in full scan and SIM modes. *Clin Chem* 1994;40:216-20.
63. Wu AHB. Cardiac troponin T: biochemical, analytical, and clinical aspects. *J Clin Immunoassay* 1994;17:45-8.

64. Wu AHB, Laios I, Green S, Gornet TG, Wong SS, Parmaley L, Tonnesen A, Plaisier B, Orlando R. Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. *Clin Chem* 1994;40:796-802.
65. Wu AHB, Valdes R Jr, Apple FS, Gornet T, Stone MA, Mayfield-Stokes S, Ingersoll-Stroubos AM, Wiler B. Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction and detection of minor myocardial injury. *Clin Chem* 1994;40:900-7.
66. Bohlmeier TJ, Wu AHB, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. *Rheum Dis Clin NA* 1994;20:845-56.
67. Wu AHB, Kelly T, McKay C, Hill D. Definitive identification of an exceptionally high methanol concentration in an intoxication of a surviving infant: methanol metabolism by first-order elimination kinetics. *J Foren Sci* 1995;40:315-20.
68. Makowski GS, Richter JJ, Moore RE, Eisma R, Ostheimer D, Onoroski M, Wu AHB. An enzyme linked immunosorbent assay for urinary screening of fentanyl citrate (Sublimaze) abuse. *Ann Clin Lab Sci* 1995;25:169-78.
69. Wu AHB. Cardiac troponins T and I in coronary artery diseases. *AACC Endo* 1995;13:79-94.
70. Laios I, Caruk R, Wu AHB. Myoglobin clearance as an early indicator for rhabdomyolysis-induced acute renal failure. *Ann Clin Lab Sci* 1995;25:179-84.
71. Wu AHB, Forte E, Casella G, Sun K, Hemphill G, Foery R, Schanzenbach H. The CEDIA assays for screening drugs of abuse in urine and the affect of adulterants. *J Foren Sci* 1995; 40:614-8.
72. Wu AHB, Lane PJ. Meta-analysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. *Clin Chem* 1995;41:1228-33. *Clin Lab* 1996;42:788.
73. Wu AHB. Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse. *Ann Clin Lab Sci* 1995;25:319-29.
74. Wu AHB. Near-patient and point-of-care testing of alcohol and drugs for abuse. *AACC Ther Drug Monit-Toxicol Update* 1995;16:225-42.
75. Sulkowski HA, Wu AHB, McCarter Y. In-vitro production of ethanol in urine by fermentation. *J Foren Sci* 1995;40:990-3.
76. Wu AHB, Abbas SA, Green S, Pearsall P, Dhakam S, Azar R, Onoroski M, Senaie A, McKay R, Waters D. The prognostic value of cardiac troponin T in patients with unstable angina. *Am J Cardiol* 1995;76:970-2.
77. Cao G, Verdon CP, Wu AH, Wang H, Prior RL. Automated oxygen radical absorbance capacity assay using the Cobas Fara II. *Clin Chem* 1995;41:1738-44.
78. Apple FS, Wu AHB, Valdes R Jr. Detection of myocardial injury by serum cardiac troponin T in hospitalized patients without myocardial infarction. *Scan J Clin Lab Invest* 1995;56:63-8.
79. Katz I, Wyndham L, Wu AHB, Apple FS, Valdes R. Cardiac troponin-T and diagnostic test evaluation. *Clin Chem* 1995;41:634-7.

80. Wu AHB, Feng YJ, Contois JH, Azar R, Waters D. Prognostic value of cardiac troponin I in chest pain patients. *Clin Chem* 1996;42:651-2. *Clin Lab* 1996;42:993-4.
81. Wu AHB. Cocaethylene. *AACC Ther Drug Monit-Toxicol Update* 1996;17:119-31.
82. Nicolau D, Wu AHB, Finnocharrio S, Nightingale C. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. *Ther Drug Monit*;1996;18:263-6.
83. Wu AHB, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinase-MB and cardiac troponin I for diagnosis of acute myocardial infarction. *Ann Clin Lab Sci* 1996;26:291-300.
84. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Continuous arteriovenous hemofiltration (CAVH) in the swine: a model for the evaluation of drug clearances. *Lab Animal Sci* 1996;46:355-7.
85. Feld S, Li G, Wu A, Felli P, Amirian J, Vaughn WK, Gornet T, Swenson C, Smalling RW. Reduction of canine infarct size by bolus intravenous administration of liposomal prostaglandin E₁ (TLC C-53): comparison with control, placebo liposomes, and continuous intravenous infusion of prostaglandin E₁. *Am Heart J* 1996;132:747-57.
86. Morris S, Wu AHB, Heller GV. New diagnostic approaches to patients with acute chest pain: role of cardiac imaging and biochemical markers. *Curr Opin Cardiol* 1996;11:386-93.
87. Abbas SA, Glazier JJ, Wu AHB, Green SF, Samedy H, Onoroski M, Pearsall LA, Waters DD, McKay RG. An analysis of the relative sensitivities of cardiac troponin T and of CK-MB in the detection of myocardial injury during percutaneous transluminal coronary angioplasty. *Clin Cardiol* 1996;19:782-6.
88. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Evaluation of myoglobin clearance during continuous hemofiltration in a swine model of acute renal failure. *Int J Art Organs* 1996,19:578-81.
89. Ostheimer D, Cremese M, Wu AHB, Hill DW. Reduction in extraction efficiency of charged particles from the ion source as the cause of matrix effects in the GC/MS analysis of drugs. *J Anal Toxicol* 1997;21:17-22.
90. Tsongalis G, Anamani DE, Wu AHB. DNA fingerprinting for identification of urine specimen donors by polymerase chain reaction amplification typing of the HLA DQA locus. *J Foren Sci* 1996;41:1031-4.
91. Wu AHB, Feng YJ, Roper E, Herbert C, Schweizer R. Cardiac troponins T and I before and after renal transplantation. *Clin Chem* 1997;43:411-2.
92. Wu AHB, Bermes EW. Report of the third conference on education in clinical chemistry. *Clin Chem* 1997;43:167-73.
93. Wu AHB, Clive J. Impact of CK-MB testing policies on hospital length of stay and laboratory costs for myocardial infarction and chest pain patients. *Clin Chem* 1997;43:326-32.
94. Wu AHB. Reducing the inappropriate utilization of clinical laboratory tests. *Conn Med* 1997;61:15-21.

95. Pervaiz S, Anderson FP, Lohman TP, Lawson CJ, Feng YJ, Wasliewcz D, Contois CJ, Wu AHB. Comparative analysis of cardiac troponin I and CK-MB as markers of acute myocardial infarction. *Clin Cardiol* 1997;20:269-71.
96. Malliaros DP, Wong SS, Wu AHB, Camphbell J, Leonard H, Houser S, Berg M, Gornet T, Brown C, Feng YJ. Quantitative determination of theophylline in serum and plasma by automated chemiluminescent immunoassay. Comparison to other methods of analysis. *Ther Drug Monit* 1997;19:224-9.
97. Wu AHB, Feng YJ, Pajor A, Gornet TA, Wong SS, Forte E. Detection and interpretation of lysergic acid diethylamide (LSD) results by immunoassay screening of urine in various testing groups. *J Anal Toxicol* 1997, 21:181-4.
98. Wu AHB. Use of cardiac markers as assessed by outcomes analysis. *Clin Biochem* 1997, 30:339-50.
99. Cassella G, Wu AHB, Shaw BR, Hill DW. The analysis of thebaine in urine for detection of poppy seed consumption. *J Anal Toxicol* 1997;21:376-83.
100. Wu AHB, Feng YJ, Nadelmann J, Acampora M, Fiedler PN. Ectopic production of creatine kinase MB: updated evaluation by mass assays. *Clin Chem* 1997;43:2006-7.
101. Wu AHB. Analytical and clinical evaluation of new diagnostic tests for myocardial damage. *Clin Chim Acta* 1998;272:11-21.
102. Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, Fram DB, Wu AHB, Waters DD. Coronary angioplasty induces a systemic inflammatory response. *Am J Cardiol* 1997, 80:1476-1478.
103. Feng YJ, Chen C, Fallon JT, Ma L, Waters DD, Wu AHB. Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute myocardial necrosis in a swine myocardial ischemic model. *Am J Clin Pathol* 1998;110:70-7.
104. Cheli CD, Morris DL, Kish L, Goldblat J, Neaman I, Allard WJ, Yeung KK, Wu AHB, Moore R, Chan DW, Fritsche HA, Schwartz MK, Very DL. Bayer Immuno 1 CA 15-3 assay: a highly precise and fully automated immunoassay for longitudinal monitoring of CA15-3 antigen levels in serum. *Clin Chem* 1998;44:765-72.
105. Giri S, Thompson PD, Taxel PM, Contois JH, Otvos J, Allen R, Ens G, Wu AHB, Waters DD. Low-dose estrogen improves serum lipids, homocysteine levels and fibrinolysis in elderly men. *Atheroscler*;1998;137:359-66.
106. Linfert DR, Wu AHB, Tsongalis G. The effect of pathologic substances and adulterants on the DNA typing of urine by the PM1 + DQ assay kit. *J Foren Sci* 1998;43:1041-5.
107. Nicolau DP, Feng YJ, Wu AHB, Bernstein SP, Nightingale CH. Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis in a model of acute renal failure. *Int J Artif Organs* 1998;21:205-9.
108. Wu AHB, Linfert DR, Tsongalis G, McKay C. DNA typing of urine: confirmation of identity for samples submitted for drugs of abuse testing. *MRO Update* 1998;January: 11.
109. Mouser JF, Wu AHB, Herson VC. Aluminum contamination of neonatal parenteral nutrition solutions and additives. *Am J Health-Sys Pharm* 1998;55:1071-2.

110. Wu AHB. Date rape drugs and other substances producing amnesia. *AACC Ther Drug Monit-Toxicol Update*, 1998;19:149-64.
111. Olatidoye AG, Wu AHB, Feng YJ, Waters D. Prognostic role of troponin T versus I in unstable angina for cardiac events with meta-analysis comparing published studies. *Am J Cardiol* 1998, 81:1405-11.
112. Wu AHB, Feng YJ, Moore R, Apple FS, McPherson P, Buechler K, Bodor G. Characterization of cardiac troponin subunit release into serum following acute myocardial infarction, and comparison of assays for troponin T and I. *Clin Chem* 1998;44:1198-208.
113. Wu AHB. Integrity of urine specimens submitted for toxicologic analysis: adulteration, mechanisms of action, and laboratory detection. *Foren Sci Rev* 1998, 10:47-65.
114. Cremese M, Wu AHB, Cassella G, Rymut K, O'Connor E, Hill D. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. *J Foren Sci* 1998,43:1220-4.
115. Fitzmaurice TF, Brown C, Rifai N, Wu AHB, Yeo KTJ. False increase of cardiac troponin I with heterophilic antibodies. *Clin Chem* 1998;44:2212-4.
116. Wu AHB. Improving the utilisation of clinical laboratory tests. *J Eval Clin Pract* 1998;4:171-81.
117. Wu AHB, Feng YJ. Biochemical differences between cTnT and cTnI and its significance for the diagnosis of acute coronary syndromes. *Eur Heart J* 1998;19suppl N:25-9.
118. Wu AHB. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. *Ann Clin Lab Sci* 1999;29:18-23.
119. Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Duh SH, Feng YJ, Jortani SA, Johnson NA, Koplén K, Mascotti K, Wu AHB. Simultaneous rapid measurement of whole blood cardiac myoglobin, creatine kinase MB, and cardiac troponin I by the Triage Cardiac Panel for detection of myocardial infarction. *Clin Chem* 1999;45:199-205.
120. Wu AHB, Contois JH, Cole T. A reflex algorithm for use of cardiac risk assessment markers. *Clin Chim Acta* 1999;180:181-93.
121. Contois JH, Gillmor RG, Moore RE, Contois LRW, Macer JL, Wu AHB. Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis. *Clin Chim Acta* 1999;282:1-14.
122. Wu AHB, Hill D, Crouch D, Hodnett NC, McCurdy H. Minimal standards for performance of toxicology tests and interpretation of results in legal cases. *J Foren Sci* 1999;44:516-22.
123. Wu AHB. A comparison of cardiac troponin T vs. cardiac Troponin I in patients with acute coronary syndromes. *Cor Art Dis* 1999;10:69-74.
124. Wu AHB. Laboratory and near patient testing for cardiac markers. *J Clin Ligand Assay* 1999;22:32-7.
125. Dati F, Panteghini M, Apple FS, Christenson RH, Mair J, Wu AH. Proposals from the IFCC Committee on Standardization of markers of Cardiac Damage (C-SMCD): strategies and concepts on standardization of cardiac marker assays. *Scan J Clin Invest* 1999;59 (suppl):113-23.

126. Wu AHB. Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. *Scan J Clin Lab Invest* 1999;59 (suppl):74-82.
127. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. *Scan J Clin Lab Invest* 1999;59 (suppl):103-12.
128. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. *Clin Chem Lab Med* 1999;37:687-93.
129. Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for use of cardiac markers in coronary artery diseases. *Clin Chem* 1999;45:1104-21.
130. Wu AHB, Ford L. Release of biochemical markers in acute coronary syndromes: ischemia or only necrosis? *Clin Chim Acta* 1999;284:161-71.
131. Wu AHB, Sexton K, Cassella G, Holtman V, Bristol B. Adulteration of urine by "Urine Luck." *Clin Chem* 1999, 45:1051-7.
132. Tsongalis GJ, Qu AHB, Silver H, Ricci A. Applications of forensic identity testing in the clinical laboratory. *Am J Clin Pathol* 1999;112(suppl 1):S93-103.
133. Christenson RH, Vaidya H, Landt Y, Bauer RS, Green SF, Apple FA, Azzazy HME, Jacob A, Magneson GR, Nag S, Wu AHB, Azzazy HME. Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material. *Clin Chem* 1999; 45:1414-23.
134. Wu AHB, Holtman V, Tsongalis GJ, Macer J. Homocysteine screening of a female Hispanic population. *Int J Mol Med* 1999;4:295-7.
135. Duca MD, Giri S, Wu AHB, Morris RS, Cyr GM, Ahlberg A, White M, Waters DD, Heller GV. Comparison of acute rest myocardial perfusion imaging and serum markers of myocardial injury in patients with chest pain syndromes. *J Nucl Cardiol* 1999; 6:570-6.
136. Wu AHB, Ghani F, Prigent F, Petry C, Armstrong G, Graff G. Reflex testing II: evaluation of an algorithm for use of cardiac markers in the assessment of emergency department patients with chest pain. *Clin Chim Acta* 1999:288:97-110.
137. Wu AHB. Obesity, anorexia, bulimia, and drugs associated with weight loss. *AACC Ther Drug Monit-Toxicol* 1999, 20:285-300.
138. Feng YJ, Draghi A, Linfert DR, Wu AHB, Tsongalis GJ. Polymorphisms in the genes for coagulation factors II, V and VII in patients with ischemic heart disease. *Arch Path Lab Med.* 1999; 123:1230-5.
139. Mockel M, Heller G, Berg K, Klefisch FR, Danne O, Muller C, Stork TV, Frei U, Wu AHB. The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. *Clin Chim Acta* 2000;293:139-55.

140. Wu AHB, Holtman V, Apple FS, Ricchiuti V, DiBello PM, Jacobsen D. Multicenter analytical evaluation of the automated IMx assay for total plasma homocysteine. *Ann Clin Lab Sci* 2000; 30:185-90.
141. Contois JH, Wu AHB, Li Z, Feroze AH, Grunenberger F, Haller J, Deslypere JP, deGroot L, Lammi-Keefe CJ. Distribution of serum apolipoproteins A-1 and B and lipoprotein(a) in European elderly: the Seneca Study. *Clin Chim Acta* 2000;295:1-12.
142. Ghani F, Wu AHB, Petry C, Armstrong G, Brown M, Graff L, Prigent F. Role of heart type fatty acid-binding protein in early detection of acute myocardial infarction. [Technical Brief] *Clin Chem* 2000; 46:718-9.
143. Wu AHB. Risk stratification of cardiac troponin in ischemic and non-ischemic cardiac diseases and procedures. *Rev Clin Biochem* 2000;21:79-88.
144. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernan FJ. Relation of C-reactive protein and extent and severity of narrowing in patients with stable angina pectoris or abnormal exercise tests. *Am J Cardiol* 2000;86:205-7.
145. Stork T, Wu AHB, Muller-Bardorff M, Gareis R, Muller R, Frei U, Katus H, Mockel, M. Myoglobin in acute coronary syndrome patients with inconclusive ECG for early diagnosis and exclusion of acute myocardial infarction and cardiac troponin T for in-hospital prognosis. *Am J Cardiol* 2000; 86:1371-4.
146. Azar RR, Rinfret S, Theroux P, Stone PH, Dakshinamurthy R, Feng WJ, Wu AH, Range G, Waters DD. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). *Eur Heart J* 2000;21:2026-32.
147. Mockel M, Gerhardt W, Heller G Jr., Klefisch F, Danne O, Maske J, Muller C, Stork T, Frei U, Wu AHB. Validation of NACB and IFCC Guidelines for the use of cardiac markers for early diagnosis and risk assessment in patients with acute coronary syndromes. *Clin Chim Acta* 2001;303:167-179.
148. Hicks JM, Haeckel R, Price CP, Lewandrowski K, Wu AHB. Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium. *Clin Chim Acta* 2001;303:1-17.
149. Hill SS, Shaw BR, Wu AHB. The respiratory and nonrespiratory effects of plasticizers, antioxidants, and other contaminants in medical PBC tubing. *Clin Chim Acta* 2001, 304:1-8.
150. Christenson RH, Apple F, Bodor G, Bunk D, Dalluge J, Duh SH, Potter J, Welch M, Wu AHB, Kahn S. Standardization of cardiac troponin I assays, Part II: round robin performance of ten candidate reference materials. *Clin Chem* 2001;47: 431-437.
151. Christenson RH, Duh SH, Sanhai W, Wu AHB, Painter P, Apple FS, Morris DL. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. *Clin Chem* 2001;47: 464-470.
152. Apple FS, Murakami M, Panteghini M, Christenson RH, Dati F, Mair J, Wu AHB. International survey on the use of cardiac markers. *Clin Chem* 2001;47:587-8.

153. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. *Clin Chem Lab Med* 2001;39:174-8.
154. Wu AHB, Tsongalis GJ. Correlation of selected single nucleotide polymorphisms of coagulation factors to risk for cardiovascular disease. *Am J Cardiol* 2001; 87:1361-6.
155. Wu AHB, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter P. Analysis of the Albumin Cobalt Binding (ACB™) Test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. *Cardiovasc Toxicol* 2001;1:147-152.
156. Sena S, Kazimi S, Wu AHB. False positive phencyclidine immunoassay result associated with venlafaxine and *o*-desmethylvenlafaxine. *Clin Chem* 2002;48:676-7.
157. Uettwiller-Geiger D, Wu AHB, Apple FS, Jevans AW, Venge P, Olson MD, Carte C, Woodrum DL, Roberts S, Chan S. Analytical performance of Beckman Coulter's Access® AccuTnI™ (Troponin I) in a multicenter evaluation. *Clin Chem* 2002;48:869-76.
158. Wu AHB, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. *Am J Cardiol* 2002;89:1300-2.
159. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Herrmann HC, McCollough PA, for the BNP Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; 347:161-7.
160. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Wold Knudsen C, Storrow AB, Abraham WT, Lamba S, Wu AHB, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, and for the BNP Multinational Study Investigators. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study. *Circulation* 2002;106:416-22.
161. Wu AHB. A primer to urine drug testing. *IVD Tech* 2002;8(6):57-64.
162. Wiecek SJ, Wu AHB, Christenson R, Rosano T, Hager D, Bailly K, Dahlen J, Chambers BS, Maisel A. A rapid B-type natriuretic peptide (BNP) assay accurately diagnoses left ventricular dysfunction and heart failure – a multi-center evaluation. *Am Heart J* 2002, 144:834-839.
163. Apple FS, Wu AHB, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. *Am Heart J* 2002;144:981-6.
164. DeRoche M, Ingardia CJ, Guerette P, Wu AHB, LaSala CA, Mandavilli SR. The use of lamellar body counts to predict fetal lung maturity in pregnancies complicated by diabetes mellitus. *Am J Obstet Gynecol* 2002;187:908-12.
165. Wu AHB. B-type natriuretic peptide for congestive heart failure. *J Clin Ligand Assay* 2002,25:155-9.

166. Wieczorek SJ, Hager D, Barry MB, Kearney L, Ferrier A, Wu, AHB. .Correlation of B-Type natriuretic peptide (BNP) to the 6-minute walk test in systolic congestive heart failure patients. *Clin Chim Acta* 2003;328:87-90.
167. Duncan B, Moyna NM, Heller GV, McGill C, Wieczorek S, Katten D, Wu A, Finta L, Velusamy M, Kelsey A, White CM. A 24-hour comparison of growth hormone concentrations in heart failure and normal subjects. *Pharmacother J* 2003;23:147-152.
168. Phillips JE, Bogema S, Fu P, Furmaga W, Wu AHB, Zic V, Hammett-Stabler C. Signify[®] ER Drug Screen Test Evaluation: comparison to Triage[®] Drug of Abuse Panel Plus TCA. *Clin Chim Acta* 2003;328:31-8.
169. Apple FS, Trinity E, Steen J, Prawner S, Wu AHB. Utilization of BNP monitoring for CHF in community hospital practice. *Clin Chim Acta* 2003;328:191-3.
170. Hill SS, Shaw BR, Wu AHB. Plasticizers, antioxidants, and other contaminants found in air delivered by PVC tubing used in respiratory therapy. *Biomed Chromatogr* 2003,17:250-62.
171. Wu AHB, Broussard LA, Hoffman RS, Kwong TC, McKay C, Moyer TP, Otten EM, Welch SL, Wax P. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. Recommendations for the Use of Laboratory Tests to Support the Impaired and Overdosed Patients from the Emergency Department. *Clin Chem* 2003;49:357-79.
172. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Wold Knudsen C, Storrow AB, Abraham WT, Lamba S, Wu AHB, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS, for the BNP Multinational Study Investigators. B-Type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Am J Kid Diseases* 2003,41:571-9.
173. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Hermann HC, Steg PG, Westheim A, Wold Knudsen C, Abraham WT, Lamba S, Wu AHB, Perez P, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. *Acad Emerg Med* 2003;10:198-204.
174. Wu AHB, Bellantoni NF. Stability of cholesterol gall stones after 165 years of burial. *J Foren Sci* 2003, 48:633-4.
175. Apple FS, Mukarami MM, Quist H, Wieczorek S, Wu AHB. Prognostic value of the Ortho Vitros cardiac troponin I assay in patients with symptoms of myocardial ischemia: risk stratification using European Society of Cardiology/American College of Cardiology recommended cutoff values. *Am J Clin Pathol* 2003; 120:114-20.
176. Wu AHB, Smith AC, Mather JF, Duncan B, White CM, Ahlberg A, McGill C, Heller H. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. *Am J Cardiol* 2003,92:628-31.

177. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA. Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. *J Am Coll Cardiol* 2003;41:2010-7.
178. Yeo KTJ, Wu AHB, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter Evaluation of the Roche NT-proBNP assay and comparison to Biosite Triage BNP assay. *Clin Chim Acta* 2003;338:107-115.
179. Wu AHB. Urine adulteration and substitution prior to drugs of abuse testing. *J Clin Ligand Assay* 2003, 26:11-18.
180. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB, Bluestein BI. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. *Clin Chim Acta* 2004,340:163-72.
181. Chapman JF, Ashwood ER, Feld R, Wu AHB. Evaluation of two-dimensional cytometric lamellar body counts on the ADVIA 120 hematology system for estimation of fetal lung maturation. *Clin Chim Acta* 2004,340:85-92.
182. Panteghini M, Pagani F, Yeo KTJ, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, Wu AHB. Evaluation of the imprecision at low-range concentration of the assays for cardiac troponin determination. *Clin Chem* 2004, 50:327-32.
183. Wu AHB, Harrison A, Maisel AS. Reduced readmission rate for alternating diagnoses of congestive heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. *Eur J Heart Fail* 2004,6:309-12.
184. Wu AHB, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. *Eur J Heart Fail* 2004,6:355-8.
185. Panteghini M, Linsinger T, Wu AHB, Dati F, Apple FS, Christenson RH, Mair J, Schimmel H. Standardization of immunoassays for measurement of myoglobin in serum. Phase I: Evaluation of candidate secondary reference materials. *Clin Chim Acta* 2004, 341:65-72.
186. Mockel M, Danne O, Schmidt A, Muller C, Dietz R, Wu AHB. Reference values for cardiac troponin I and T in a goal-oriented concept of health: cardiac marker values in a series of outpatients without acute coronary syndromes. *Clin Chim Acta* 2004, 342:83-6.
187. Wu AHB Packer M, Smith A, Bijou R, Fink F, Mair J, Wallentin L, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Despres N, Bluestein B, Ghani F. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. *Clin Chem* 2004, 50: 867-73.
188. Wu AHB. Quality specifications in thyroid diseases. *Clin Chim Acta* 2004, 2004,346:73-7.

189. Wu AHB, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. *Clin Chim Acta* 2004,346:211-9.
190. Maisel AS, Clopton P, Krishnaswamy P, Nowak, RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg G, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Bhalla V, Hermann HC, Aumont MC, McCullough PA. The impact of age, race and gender on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) Multinational Study. *Am Heart J* 2004, 147:1078-84.
191. Wu AHB, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in heart failure patients. *Am J Cardiol* 2004, 93:1562-3.
192. Wu AHB, Omland T, Duc P, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Wold Knudsen C, Storrow AB, Abraham WT, Perez A, Kamin R, Clopton P, Maisel AS, McCullough PA, for the Breathing Not Properly Multinational Study Investigators. The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. *Diabetes Care* 2004, 27:2398-2404.
193. Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB, McCord J, nowak RM, Aumont MC, Duc P, Hollander JE, Wu AHB, McCullough PA, Maisel AS. Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. *Am J Med* 2004;116:363-8.
194. Duncan B, Wiczorek S, Wu A, Moyna NM, Heller GV, White CM. A 24-hour comparison of whole blood B-type natriuretic peptide. Concentrations in heart failure and normal subjects. *N Engl J Pharm* 2004;1:30-3.
195. Yaworsky DC, Wu AHB, Hill DW. The use of plasma metanephrine to normetanephrine ratio to determine epinephrine poisoning. *Clin Chim Acta* 2005, 353:31-44.
196. Apple FS, Mair J, Ravkilde J, Christenson RH, Franca P, Tate J, Wu AHB, Panteghini M, Jaffe A. Quality specifications for B-type natriuretic peptide assays. *Clin Chem* 2005, 51:486-91.
197. Tang WHW, Philip K, Hazen SL, Cole CE, Pepoy M, Smith A Neale S, Van Lente F, Francis GS, Wu AHB. Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure: implications for population screening. *Clin Corner* 2005, 7(suppl 1):S18-S24.
198. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel R, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem* 2005, 51:810-824.
199. Wu AHB. Markers for early cardiovascular disease detection. *Scan J Clin Lab Invest* 2005, 64(suppl 240):112-121.
200. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu A, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A, Omland T. Predictors and significance of an elevated B-type natriuretic peptide concentration in

- dyspneic patients without a diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Ann Emerg Med* 2005, 45:573-80.
201. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, McCord J, Nowak RM, Hollander JE, Storrow AB, Abraham WT, McCullough PA, Maisel A. Impact of atrial fibrillation on the diagnostic performance of b-type natriuretic peptide concentration in dyspneic patients an analysis from the breathing not properly multinational study. *J Am Coll Cardiol*; 46:838-844, 2005.
 202. Apple FS, Parvin CA, Christenson RH, Wu AHB, Jaffe AS. Validation of the 99th percentile cutoff for cardiac troponin monitoring for detection of myocardial infarction. *Clin Chem* 2005, 51:2198-2200.
 203. Singer M, Mirhej G, Shaw S, Salaheen H, Vivian J, Hastings E, Rohena L, Jennings D, Navarro J, Santelices C, Wu AHB, Smith A, Perez A. When the drug of choice is a drug of confusion: embalming fluid use in inner city Hartford CT. *J Ethn Sub Abuse* 2005, 4:73-96.
 204. Wu AHB, Omland T, McCord J, Nowak RM, Hollander JE, Duc P, Storrow AB, Abraham WT, Clopton P, Steg G, Knudsen CW, Kazanegra R, Herrmann HC, Maisel AS, McCullough PA. The relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. *Am J Hematol* 2005,80:174-80.
 205. Ruano G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR, Seip R, Wu AHB. Physiogenomic analysis links serum CK activities during statin therapy to vascular smooth muscle homeostasis. *Pharmacogen* 2005;6:865-72.
 206. Strunk A, Bhalla V, Clopton P, Nowak RM, McCord J, Hollander JE, Duc P, Storrow AB, Abraham WT, Wu AHB, Steg G, Perez A, Kazanegra R, Herrmann HC, Aumont MC, McCullough PA, Maisel A, for the BNP Multinational Study Investigators. Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: Results from the Breathing Not Properly Multinational Study. *Am J Med* 119(1):69.e1-69.e11, 2006.
 207. Kupchak P, Wu, AHB, Ghani F, Newby, LK, Ohman EH, Christenson RH. The influence of imprecision on receiver-operating characteristic curve analysis for cardiac markers. *Clin Chem* 2006, 52: 752-3.
 208. Wu AHB. Point-of-care testing for conventional cardiac markers. *J Point Care* 2006;5:20-4.
 209. Ruano G, Makowski G, Windemuth A, Kocherla M, Weiss S, Goethe JW, Bower B, Wu AHB, Thompson P. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. *Person Med* 2006;3:131-7.
 210. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg PG, Westheim A, Wold Knudsen C, Perez A, Kazanegra R, Hermann HC, McCullough PA, Maisel AS. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute

- heart failure: results from the Breathing Not Properly Multinational Study. *Am Heart J* 2006;151:999-1005.
211. Wu AHB. A selected history and future of immunoassay development and applications in clinical chemistry. *Clin Chim Acta* 2006;369:119-24.
 212. Christenson RH, Duh SH, Apple FS, Bodor GS, Bunk DM, Panteghini M, Welch MJ, Wu AHB, Kahn SE, for the American Association for Clinical Chemistry Cardiac Troponin I Standardization Committee. Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. *Clin Chem* 2006, 52:1685-92.
 213. Wu AHB, Fukushima F, Puskas R, Todd J, Goix P. Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. *Clin Chem* 2006; 52:2157-9.
 214. Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biological variation in interpretation of results. *Am Heart J.* 2006, 152:828-34.
 215. Wu AHB. Plasma BNP/NT-proBNP assays: what do they target and what other things might they recognize? *Heart Fail Clin* 2006, 2:291-8.
 216. Wang P, Stone JA, Chen KH, Gross SF, Haller CA, Wu AHB. Hydrolysis methods impacts recovery and detection of urine opiates. *J Anal Toxicol* 2006, 30:570-6.
 217. Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A Wu AHB, Ko N, Gelb AW, Lawton MT, Smith WS, Young W, Zaroff J. Cardiovascular predictors of inpatient mortality after subarachnoid hemorrhage. *Neurocrit Care*, 2006, 5:102-7.
 218. Wu AHB, Schultz K, Gomez C, Smith A, Tabas JA. Laboratory testing for salicylate resistance. *J Clin Ligand Assay* 2006, 29:60-3.
 219. Fiebig E, Wu AHB, Krombach J, Tang J, Nguyen KA, Toy P. Transfusion Related Acute Lung Injury (TRALI) and transfusion associated circulatory overload (TACO)- mutually exclusive or coexisting entities [Letter]? *Transfus* 2006, 47:171-2.
 220. Bibbins-Domingo K, Gupta R, Na B, Wu AHB, Schiller NB, Whooley MA. N-terminal pro-B-type natriuretic peptide and incident heart failure in ambulatory patients with coronary disease: data from the Heart and Soul Study. *JAMA* 2007; 297:169-176.
 221. Corteville DC, Bibbins-Domingo K, Wu AHB, Ali S, Schiller NB, Whooley MA. NT-proBNP rules out ventricular dysfunction in patients with coronary disease: Data from the Heart and Soul Study *Arch Int Med* 2007; 167:483-9.
 222. Tran MN, Wu AHB, Hill DW. Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal ethanol metabolism. *Tox Letters* 2007, 169:245-52.
 223. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. *Clin Chem* 2007, 53:552-74 and *Circulation* 2007; 115:e356-75.

224. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of acute coronary syndromes. *Clin Chem* 2007, 53:547-51 and *Circulation* 2007; 115:e352-5.
225. Joelson D, Wu AHB, Fiebig E. Need for erythrocyte folate measurements in the post folic acid supplementation among indigent populations. *Arch Path Lab Med* 2007,131:477-80.
226. Wu AHB, Smith A, McComb R, Bowers, Jr., GN, Makowski GS, McKay C, Vena J, McDonagh J, Hopfer S, Sena SF, Malkus HL, Forte E, Kelly K. State-wide hospital clinical laboratory plan for measuring cholinesterase activity for individuals suspected of exposure to nerve gas chemical weapons. *Clin Toxicol* 2007, accepted.
227. Perez A, McKay C, Vena J, O'Sullivan D, Smith A, Wu AHB. Acetaminophen urinary kinetics following suprathreshold non-toxic ingestion. *J Clin Tox* 2006, in preparation.
228. Januzzi JL, Peacock WF, Jesse RL, Newell JB, Baggish AL, Sakhuja R, O'Donoghue M, Chen AA, van Kimmenade RRJ, Sluss P, Lee-Lawandrowski E, Wu AHB. Measurement of soluble ST2 concentrations for the evaluation of patients with acute dyspnea. *J Am Coll Cardiol* 2007, accepted.
229. Kopelnik A, Yarlagadda S, Pajendran P, Zhu-Shimoni J, Fisher LA, Ko N, Lawton MT, Wu AHB, Young WL, Zaroff JG. Serum levels of inflammatory cytokines and neurocardiogenic injury after subarachnoid hemorrhage. *Circulation* 2007; Submitted.
230. Desai AS, Bibbins-Domingo K, Shlipak MG, Wu ALH, Ali S, Whooley MA. Association between anemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP) inpatients without clinical heart failure: findings from the Heart and Soul Study. *Eur J Cardiac Failure* 2007 submitted.
231. Ruano G, Thompson PD, Windemuth A, Dande A, Kocherla M, Seip RL, Smith A, Holford TR, Wu AHB. Physiogenomic analysis links myalgia during statin therapy to serotonin receptors HTR3B and HTR7. *Muscle Nerve* 2007; accepted.
232. Ng VL, Wong A, Tabas J, Fiebig E, Wu AHB. Sensitive d-dimer tests: too sensitive for inpatient testing. 2007; in preparation.
233. Wu AHB. Early detection of acute coronary syndromes and risk stratification by multibiomarker analysis. *Biomark Med* 2007, 1:45-58.
234. Wu AHB, Wang P, Smith A, Haller C, Linder MW, Valdes, RL Jr. A comparison of pharmacogenomic modeling algorithms for warfarin dosing using genotyping for cytochrome (CYP) 2C9 and vitamin K reductase complex 1 (VKORC1) and the effect of ethnicity. *Stroke* 2007, submitted.
235. Wu AHB. The use of genetic and non-genetic factors in warfarin dosing algorithms. *Pharmacogen* 2007, in press.
236. Wu AHB, Apple FS, Jaffe AS, Jesse RL, Morrow DA, Newby K, Ravkilde J, Francis GL, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine

- Practice Guidelines: use of cardiac troponin and the natriuretic peptides for etiologies other than acute coronary syndromes and heart failure. *Clin Chem* 2007, submitted.
237. Brenden CK, Yancy CW, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann H, McCullough PA, Maisel AS. Racial disparities in clinical judgement of heart failure: analysis from the Breathing Not Properly Multinational Study. In preparation, 2007.
 238. Maisel AS, Bhalla MA, Wold Knudsen C, Gardetto N, McCord J, Nowak RM, Hollander JE, Wu AHB, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumong MC, Westheim A, Perez A, Kamin R, Kazanegra R, Hermann HC, McCullough PA. Utility of B-type natriuretic peptide levels in predicting outcome of hospitalized patients with congestive heart failure: results of the Breathing Not Properly (BNP) Multinational Study. *J Am Coll Cardiol* 2005, in preparation.
 239. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate JR, WU AHB, Ler R, Apple FS. Cross-reactivity of BNP, NT-proBNP and proBNP in commercial BNP and NT-proBNP assays: preliminary observations. *Clin Chem* 2007, submitted.

PATENTS

1. Armstrong EG, Petry C, Wu AHB, Wagner G. Reflex algorithm for early and cost effective diagnosis of myocardial infarction suitable for automated diagnostic platforms. U.S. Patent 6,099,469, 2000.
2. Chapman-Montgomery ES, Okrongly D, Ahnardi CE, Wu A, Gervas An. Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress. U.S. Patent pending.

NON-PEER REVIEWED PUBLICATIONS

LETTERS, NOTES

1. McComb RB, Wu AHB, Schoppman A, Inman S. User experience of the Roche Cobas Bio. *Clin Instrum System* 1981;2(5):4-5.
2. Wu AHB, Rotunno T, Malmstadt HV. Microcomputer-controlled photodiode array spectrophotometric titrator. *Amer Lab* 1982;13:16-34, and *Int Lab* 1982;12:16-28.
3. Wu AHB, Ohneck J, Klaus E, McComb RB. A washer-dryer system for cuvette rotors used in the Cobas-Bio Centrifugal Analyzer [Letter]. *Clin Chem* 1982;28:2188-9.
4. Wu AHB, McComb RB. Permanent vs. disposable rotors for centrifugal analyzers [Letter]. *Clin Chem* 1983;29:990-1.
5. Wu AHB. Current methods and limitations for fractionating creatine kinase isoenzymes. *Clin Lab* 1984;8:203-17.
6. Wu AHB. CK-MB assay methods. A comparison. *Lab Man* 1985;23(1):44-50.
7. Wu AHB. Support researchers. *Clin Chem News* 1985;11(12):4.
8. Wu AHB. Job market for clinical chemists is still strong. *Clin Chem News* 1987;13(5):5.

9. Wu AHB, Brockie R. Creatine kinase isoforms in acute myocardial infarction. College of American Pathologists, "Check Sample Program," in Clin Chem 1987;87-8 ((CC-186).
10. Wu AHB. User experience, The Helena Rep. Clin Instrum Systems 1988;10(1):5-6.
11. Wu AHB. Analysis of creatine kinase isoenzymes and isoforms. Clin Lab 1989;3(3):155-63.
12. Wu AHB. Introduction to Hypertension: Pathophysiology and Control. The Proceedings of the 14th Annual A.O. Beckman Conference. Clin Chem 1991;37:1809-10.
13. Wu AHB. Methods for creatine kinase isoform analysis. Clin Chem News 1992;17(6):19-20.
14. Wu AHB. Clinical Chemistry Questions and Answers: Fetal lung maturity assays. JIFCC 1993;5:154.
15. Apple FS, Wu AHB. Cardiac markers poster. Clin Chem News 1993;19(4):8.
16. Wu AHB. Clinical Chemistry Questions and Answers: Bedside drug testing. JIFCC 1994;6:14.
17. Wu AHB, Apple FS, Valdes R Jr. Cardiac troponin-T and diagnostic test evaluation. [Letter]. Clin Chem 1995;41:634-6.
18. Wu AHB. Cardiac troponin I: a tool for the times? Behring Mon 1996;13(1):1-6.
19. Wu AHB. New strategies, tools emerge for drugs of abuse. Advance Lab Med 1996;8(8):14-19.
20. Wu AHB, Jesse RL. Triaging the chest pain patient. Clin Lab News 1996;22:poster insert.
21. Wu AHB. Clinical Chemistry Questions and Answers: workstation consolidation. JIFCC 1996;9:170.
22. Wu AHB. A review on the methods and interpretation of alcohol (ethanol) measurements. MRO Update 1997;March:6-14.
23. Mascotti K, Wu AHB. Clinical Chemistry Questions and Answers: unbundling the chemistry profile. JIFCC 1997, 9(1):36.
24. Wu AHB. Detecting myocardial injury. Advance 1997;6:82-5.
25. Wu AHB. Impact of a high precision prostate specific antigen (PSA) assay on management of adenocarcinoma of the prostate: a case report. Bayer Internet 1998 (http://www.bayerdiag/whats_new/library/on-line/immuno/psa.html).
26. Schwartz JG, Wu AHB. Questions and answers on diagnosis of myocardial infarction. CAP Today 1990;4(7):33-4.
27. Wu AHB, Rymut K. The adulteration of urine drug testing results with "Klear." Ther Drug Monit Clin Tox Newsletter 1997, 12(4):1-2.
28. Wu AHB. Cardiospecificity of biochemical markers in acute coronary syndromes. Intensivmed 1998;35:165-6.
29. Wu AHB. The value of cardiac markers for risk stratification in patients with acute coronary syndromes. Clin Lab News 1998,24(6):12-6.
30. Wu AHB. Clinical Chemistry Questions and Answers: Improving the diagnostic accuracy of PSA. JIFCC 1998;10:81.

31. Kidwell DA, Smith FP, Crouch D, Wu AHB. Commentary on minimal standards for the performance and interpretation of toxicology tests in legal proceedings. *J Foren Sci* 2000;45:237-9.
32. Bogusz MJ, Crouch D, Wu AHB. Further commentary. *J Foren Sci* 2000;45:1659-60.
33. Wu AHB, Jialal I. How Specific is Cardiac Troponin? [Editorial]. *Am J Clin Pathol* 2000; 114:509-11.
34. Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing. [Editorial]. *Chem Chem* 2001; 47:377-79.
35. Wu AHB. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression. [Editorial]. *Inten Care Med* 2001;27:959-60.
36. Wu AHB. Clinical utility of cardiac troponin in acute coronary syndromes. Proceedings of the DPC Symposia and meeting in the Benelux, 1999.
37. Makowski GS, Hopfer SM, Tsongalis GJ, Wu AHB. Changes in academic productivity: implications for clinical laboratory research and development. [Letter]. *Clin Chem* 2000;46:303-5.
38. Wu AHB. Experience for police drug ID takes hit. Recognizing toluene not enough. The Forensic Panel, 2001; www.forensicpanel.com.
39. Wu AHB. B-type natriuretic peptide and its clinical utility in patients with heart failure. *Med Lab Observer* 2001;33(10):10-14.
40. Wu AHB. Point-of-care testing for cardiac markers: has the time come? *Point of Care*. 2002, 1:39-41.
41. Wu AHB. Cardiac markers: cost effective triage for myocardial infarction admission and therapy. *Med Lab Observer* 2002;34(6):36-40.
42. Wu AHB. Laboratory markers of CHF. *Advance* 2002;11(4):54-60.
43. Wu AHB, Valdes R Jr, Hawker CD. Guidelines and recommendations in laboratory medicine [letter]. *Clin Chem* 2002, 48:1135-6.
44. Wu AHB, Apple FS. Reporting of cardiac troponin concentration [letter]. *Clin Chem* 2002; 48:2077-82.
45. Wu AHB. The ischemia-modified albumin biomarker for myocardial ischemia. *Med Lab Observer* 2003;35(6):36-40.
46. Wu AHB. The role of cardiac troponin in the recent redefinition of acute myocardial infarction. *Clin Lab Sci* 2004, 17:50-2.
47. Wu ABH. Reflex testing III: efficient use of laboratory markers for anemia [Letter]. *Clin Chim Acta* 2004, 343:241-3.
48. Wu AHB. Clinical laboratory diagnosis of stroke. *Life Sci BTR* 2004, 1(2):30-1.
49. Wu AHB, Apple FS, Jaffe A, Galvani M. British Cardiac Society's troponin cutoff concentration for myocardial infarction: "back to the future?" [eLetter]. *Heart* 2004. <http://heart.bmjournals.com/cgi/eletters/90/6/603>.
50. Wu AHB. Stroke diagnosis. *ASCP Check Sample Program*, 2005, 45(8):113-26.

51. Joelson DW, Wu AHB. BNP for screening and monitoring of heart failure. *ASCP Check Sample Program*, 2006, 46(5):55-66.
52. Wu AHB. Point-of-care testing for cardiac markers at the bedside. *Bus Brief Emerg Med Review* 2005, 42-3.
<http://www.touchbriefings.com/cdps/cditem.cfm?NID=1334&CID=5&CFID=2346301&CFTOKEN=9#Contents>.
53. Wu AHB. Update on the analytical aspects and clinical applications of natriuretic peptides. *Advance* 2006, 15(1):34-8.
54. Wu AHB, Gross S. Response to Tips from the clinical experts. *MLO* 2006, 38(2):6-8.
55. Wu AHB. Toxicology testing in the emergency department: meeting changing needs. *Clin Lab News* 2006;32(9):14-6.
56. Wu AHB. Cardiac troponin: of the cardiac physician. *Foe to the cardiac patient?* [Editorial]. *Circulation* 2006, 114:1673-74.
57. Thompson PD, Apple FS, Wu AHB. Marathoner's heart. [Editorial]. *Circulation* 2006, 114:2306-8.
58. Wang P, Haller CA, Wu AHB. Crystal methamphetamine: abuse, toxicity and laboratory detection. *Clin Foren Toxicol Newsletter*, AACC Press, 2007.
59. Bailey H, Wu AHB. Bright green serum. *Images in clinical medicine*. *N Engl J Med* 2007, accepted.
60. Wu AHB, Guglielmo J, Hamill T, Haller C. Clinical laboratory needs for pharmacogenomic testing [Letter]. *Ann Intern Med* 2007, online.
<http://www.annals.org/cgi/eletters/145/10/749>

BOOK CHAPTERS:

1. Wu AHB. Ionized Calcium in Acute Care Medicine: Focus on liver transplantation. In *Ionized Calcium: Its determination and clinical usefulness*. Moran, RF, ed, 1987:36-43.
2. Wu AHB: Liver cancer. In: *Textbook of Clinical Lab Science*, Davis BG, Bishop ML, Mass D, eds., Lippincott, Philadelphia, 1988. Chapter 34, pp. 381-90.
3. Wu AHB, Sell S. Markers for hepatic carcinoma. In: *Immunodiagnosis of Cancer*, 2nd ed., Herberman RB, Mercer DW, eds., Dekker, New York, 1990:403-22.
4. Wu AHB. Enzymes in cardiovascular and skeletal muscular diseases. In: *Clinical Chemistry*, 3rd ed. Wu AHB, Chan KM, Lott JA, Hursting M. Health and Education Resources, Bethesda, MD, 1991:47-54.
5. Onigbinde TA, Wu AHB. Analytical techniques and instrumentation. In: *Clinical Chemistry, Principles, Procedures, and Correlation*, 2nd ed. Bishop ML, Duben-Engelkirk JL, Fody EP, eds., Lippincott, Philadelphia, 1991:103-32. 3rd edition: Laios I, Wu AHB, 1995:97-126, 4th edition.
6. Wu AHB. Renal Function. 2nd ed. Bishop ML, Duben-Engelkirk JL, Fody EP, eds., Lippincott, Philadelphia:1991:453-71. 3rd edition: Elie-Carlledge S, Wu AHB, 1996:359-80. 4th ed: Skarzynski C, Wu AHB.

7. Wu AHB. Requirements and considerations for clinical laboratory capabilities. In: Proceedings of the Space Station Freedom Clinical Experts Seminar, NASA Conference Pub. 10069, Houston, 1991:59-61.
8. Wu AHB. Chapter 11. Diagnostic Enzymology. In: Clinical Laboratory Medicine, McClatchey KM, ed., 1st ed., Lippincott Williams & Wilkins, Baltimore, MD, 1993:259-86. 2nd ed., 2002: 281-305.
9. Wu AHB. Myocardial Infarction. In: Professional Practice in Clinical Chemistry: A Review, D.R. Dufour, ed., American Association for Clinical Chemistry, Washington, DC, 1993: 117-136, 1995: 109-130, 1997: 303-324.
10. Wu AHB. Pancreas. In: Professional Practice in Clinical Chemistry: A Review, D.R. Dufour, ed., American Association for Clinical Chemistry, Washington, DC, 1993:137-152, 1995:131-148, 1997: 325-346.
11. Moore R, Luczyk K, Wu AHB. Workstation optimization. In: Handbook of Clinical Laboratory Automation, Robotics and Optimization, Kost GJ, Welsh J, Wiley, 1996:497-514.
12. Wu AHB. Immunoassays for drugs of abuse. In: Analysis for Drugs of Abuse: Instrumental Methods & Techniques, Ryan TW, ed., 1996.
13. Wu AHB. Cardiac markers for coronary artery diseases: need for random access testing. Proceedings of the 5th Technicon Immuno 1 International Symposium, Paris, Chase Medical Comm., Wilton, CT, 1996:65-9.
14. Tsongalis GJ, Rezuke WN, Wu AHB. An epidemiological study to evaluate the incidence of activated protein C resistance in the general population using a PCR-mediated restriction fragment length polymorphism assay: implications for the critical care patient. In: Advances in Critical Care Testing. List WF, Muller MM, McQueen MJ, eds., Springer, Berlin: 1996;211-22.
15. McKay CA, Wu AHB. Diagnostic modalities for the toxicology patient. In: Emergency Medicine: The Core Curriculum. Aghababian ed., Lippincott-Raven, New York, 1998;984-992.
16. Wu AHB. Introduction to coronary artery disease and cardiac markers In: Cardiac Markers. Wu AHB ed., Humana Press, Totowa, NJ:1998:3-20.
17. Giri S, Waters DD, Wu AHB. Pathophysiology of acute coronary syndromes. In: Cardiac Markers. Wu AHB ed., Humana Press, Totowa, NJ:1998:21-44.
18. Wu AHB. Creatine kinase, isoenzymes, and variants. In: Cardiac Markers. Wu AHB ed., Humana Press, Totowa, NJ:1998:113-26.
19. Wu AHB. CK-MB activity assays. In: Cardiac Markers. Wu AHB ed., Humana Press, Totowa, NJ:1998:127-42.
20. Wu AHB. New biochemical markers for heart disease. In: Cardiac Markers. Wu AHB ed., Humana Press, Totowa, NJ:1998:218-94.
21. Wu AHB. Disease reflex algorithms for acute and long-term management of cardiac patients. Proceedings of the 2nd and 3rd International Bayer Diagnostics Laboratory

- Testing Symposium, New York City NY and Vienna Austria, Chase Medical Comm., Wilton, CT, 1998:38-40 and 38-41.
22. Wu AHB. Role of serum biochemical markers in clinical trials. In: Myocardial Damage: Early Detection by Novel Biochemical Markers. Kaski JC, Holt DW, Kluwer Publishers, 1998:189-200.
 23. Wu AHB. Point-of-care testing and the patient with chest pain. In: Point-of-care testing. Price CP, Hicks J, ed., Am Assoc Clin Chem, Washington, DC: 1999:426-44.
 24. Wu AHB. Cardiac markers. In: The Immunoassay Handbook, Wild D, 2nd ed., Nature Publishing, London, UK:2001: 612-34. 3rd ed., 2005:649-663.
 25. Wu AHB. Cardiac markers. In: Encyclopedia of Molecular Medicine. Creighton TE, ed. John Wiley & Sons, New York, NY;2001:
 26. Wu AHB. Cardiac markers. In: Clinical Chemistry: Laboratory Management and Clinical Correlations. Lewandrowski, ed., Lippincott Williams & Wilkins, New York, 2002:671-88.
 27. Yeo KTJ, Quinn-Hall KS, Bateman SW, Fischer GA, Wieczorek S, Wu AHB. The functional sensitivity of cardiac troponin assays and its implications for risk-stratification for patients with acute coronary syndromes. In: Markers in Cardiology. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:23-30.
 27. Apple FS, Adams JE, Wu AHB, Jaffe AS. Report on a survey of analytical and clinical characteristics of commercial cardiac troponin assays. In: Markers in Cardiology. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:31-4.
 28. Wu AHB. Urine adulteration prior to testing for drugs of abuse. In: The Clinical Toxicology Laboratory. Contemporary Practice of Poisoning Evaluation. Shaw LM, Kwong TC, eds., AACC Press, 2001: 157-72.
 29. Wu AHB. Point-of-care testing for drugs of abuse. In: The Clinical Toxicology Laboratory. Contemporary Practice of Poisoning Evaluation. Shaw LM, Kwong TC, ed., AACC Press, 2001: 145-56.
 30. Wu AHB. Analytical issues affecting the clinical performance of cardiac troponin assays. In: Markers in Cardiology. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. AHA Monograph, Armonk, NY, 2001:1-12.
 31. Wu AHB. Onsite Tests for Therapeutic Drugs. In: Onsite Drug Testing. Jenkins A, Goldberger B, ed. Humana Press, Totowa, NJ:2002:11-24.
 32. Wu AHB. Point-of-care drug testing. In: Point-of-care testing: principles, management, and clinical practice. Kost GJ, ed., Lippincott Williams & Wilkins, Baltimore, 2002:253-66.
 33. Wu AHB. The rationale for point-of-care testing (POCT) for drugs of abuse and ethyl alcohol. In: Point of care testing: performance improvement and evidence-based outcomes. Nichols JH, ed., Marcel Dekker, Inc., New York, NY, 2003:439-53.
 34. Wu AHB. Polymorphisms related to acute coronary syndromes and heart failure. Potential targets for pharmacogenomics. In: Cardiac Markers, 2nd ed., Wu AHB, ed., Humana Press, Totowa, NJ: 2003:437-58.

35. Wu AHB, Mockel M, Danne O, Fagan G, Keffer J. Ischemia-modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponin. In: *Cardiac Markers*, 2nd ed., Wu AHB, ed., Humana Press, Totowa, NJ: 2003:259-77.
36. Wu AHB. Analytical issues and the evolution of cutoff concentrations for cardiac markers. In: *Cardiac Markers*, 2nd ed., Wu AHB, ed., Humana Press, Totowa, NJ: 2003:231-41.
37. Wu AHB. Molecular pathogenesis of cardiovascular disease. In: *Molecular Diagnostics For the Clinical Laboratorian*, 2nd ed., Coleman WB, Tsongalis GJ, eds., Humana Press, Totowa, NJ: 2005:295-308.
38. Wu AHB. Analytical issues for clinical use of cardiac troponin. In: *Cardiovascular Biomarkers. Pathophysiology and Disease Management*. Morrow DA, ed., Human Press, Totowa, NJ: 2006:27-40.
39. Wu AHB. Basics of natriuretic peptides: practical aspects of assays, potential analytic confounders, and clinical interpretation. In: "Markers in Cardiology: A Contemporary Case-Oriented Approach." Adams JE, Jaffe A, Apple FS, eds. 2007, pp. 128-133.
40. Wu AHB. Myocardial injury: pathophysiology of coronary artery disease. In: "Contemporary Practice in Clinical Chemistry" Clarke W, Dufour DR, eds., 2006:261-8.
41. Wu AHB. Normal anatomy and physiology of the pancreas. In: "Contemporary Practice in Clinical Chemistry" Clarke W, Dufour DR, eds., 2006:281-8.
42. Wu AHB. Standards for reporting of diagnostic accuracy (STARD): relevance to clinical laboratory studies. In: "Evidence-based laboratory medicine. From principles to outcomes." 2nd ed., Price CP, Christenson RH, eds. 2007;in press.

BOOKS AND MONOGRAPHS:

1. Brewster MA, Turley CP, Wu AHB. *Clinical Chemistry Self-Assessment*, 2nd ed., AACC, Washington, DC, 1989.
2. Wu AHB, Chan KM, Hursting MJ, Lott JA, Spillman T, Wheaton RN. *Clinical Chemistry*, 2nd ed., Health Education Resources, Bethesda, MD, 1991.
3. Wu AHB. *Cardiac Markers*. Humana Press Inc., Totowa, NJ, 1998.
4. Wu AHB, Moore R, Tsongalis G, Burnett RW. *Clinical Chemistry Self-Assessment*, 3rd ed., AACC, Washington, DC, 2000.
5. Wu AHB, Apple FS, Warshaw MM. Recommendations for the use of cardiac markers in coronary artery diseases. National Academy of Clinical Biochemistry, Washington, DC:2000.
6. Adams JE, Jaffe AS, Apple FS, Wu AHB, eds. *Markers in Cardiology*. AHA Monograph, Armonk, NY, 2001.
7. Wu AHB. *Cardiac Markers*, 2nd ed. Humana Press Inc., Totowa, NJ, 2003.
8. Adams J, Apple F, Christenson R, Kahn S, Robberts W, Sacks D, Wu AHB. *Laboratory testing for cardiac disease:options and answers*. AACC, Washington, DC, 2003.

9. Wu AHB, editor. Tietz Clinical Guide to Laboratory Tests, 4th ed., Elsevier Science, New York, 2006.

Updated: 1/06